120 related articles for article (PubMed ID: 38053420)
1. Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
Dong X; Wang Y; Wang S; Li C; Zhang M; Hou F
Arch Esp Urol; 2023 Nov; 76(9):657-665. PubMed ID: 38053420
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor.
Shao LJ; Wang HJ; Wang JR; Yuan XF; Sha Q
Pak J Med Sci; 2022; 38(5):1243-1249. PubMed ID: 35799745
[TBL] [Abstract][Full Text] [Related]
4. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
5. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
Wang XQ; Liu J; Lin HS; Hou W
Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of NSCLC ancillary treatment with compound Kushen injection through immunocompetence regulation: A systematic review and meta-analysis.
Wang D; Xu Y; Huang T; Peng W; Zhu D; Zhou X; Wu Q
Phytomedicine; 2022 Sep; 104():154315. PubMed ID: 35868145
[TBL] [Abstract][Full Text] [Related]
7. The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
Wang L; Huang S; Zhang P; Li H; Li Z; Xue L; Wang Z; Chen Q; Fu D; Luo Q; Li H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8945-8949. PubMed ID: 37160625
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao M; Ma CK; Ma J; Chen HG; Xue W
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
[TBL] [Abstract][Full Text] [Related]
9. Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Tong S; Hu X; Li Y
Urol Oncol; 2022 Sep; 40(9):412.e1-412.e8. PubMed ID: 35718638
[TBL] [Abstract][Full Text] [Related]
10. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.
Böhle A; Leyh H; Frei C; Kühn M; Tschada R; Pottek T; Wagner W; Knispel HH; von Pokrzywnitzki W; Zorlu F; Helsberg K; Lübben B; Soldatenkova V; Stoffregen C; Büttner H;
Eur Urol; 2009 Sep; 56(3):495-503. PubMed ID: 19560257
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
[TBL] [Abstract][Full Text] [Related]
12. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
[TBL] [Abstract][Full Text] [Related]
13. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
[TBL] [Abstract][Full Text] [Related]
14. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
[TBL] [Abstract][Full Text] [Related]
15. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
16. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
17. Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Wang TW; Yuan H; Diao WL; Yang R; Zhao XZ; Guo HQ
BMC Urol; 2019 Oct; 19(1):90. PubMed ID: 31615492
[TBL] [Abstract][Full Text] [Related]
18. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Lightfoot AJ; Breyer BN; Rosevear HM; Erickson BA; Konety BR; O'Donnell MA
Urol Oncol; 2014 Jan; 32(1):35.e15-9. PubMed ID: 23510863
[TBL] [Abstract][Full Text] [Related]
19. Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Hori S; Miyake M; Tatsumi Y; Onishi S; Morizawa Y; Nakai Y; Tanaka N; Fujimoto K
PLoS One; 2017; 12(4):e0175494. PubMed ID: 28406993
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
